Literature DB >> 1724554

Effect of 2-guanidinoethanol on levels of monoamines and their metabolites in the rat brain.

I Yokoi1, T Itoh, K Yufu, K Akiyama, M Satoh, S Murakami, H Kabuto, A Mori.   

Abstract

The contents of monoamines and their metabolites in rat brains 3 hours after the intracerebroventricular injection of 6 mumol of 2-guanidino-ethanol (GEt) were measured by HPLC. GEt which is a configurational analogue of 4-aminobutanoic acid (GABA) induced severe running fits and tonic-clonic convulsions as well as epileptic discharges. In GEt-administered rats, dopamine (DA) decreased in the cortex, hippocampus and hypothalamus. 3,4-Dihydroxyphenylacetic acid (DOPAC) increased to about the same level in all brain regions, therefore the distribution of DOPAC appeared to be homogeneous in the brain. The homovanillic acid levels also increased in the striatum and hippocampus. No significant change in the norepinephrine contents was observed in any region. The turnover ratio of DA increased significantly except in the striatum. Serotonin levels increased in the hypothalamus and midbrain by GEt administration, though 5-hydroxyindoleacetic acid levels showed no change in any of the brain regions. These data suggest that the activity of dopaminergic and serotonergic neurons are increased by GEt.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724554     DOI: 10.1007/bf00966595

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  22 in total

1.  Evidence for an inhibitory gabergic control of the meso-limbic dopamine neurons: possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs.

Authors:  K Fuxe; T Hökfelt; A Ljungdahl; L Agnati; O Johansson; M Perez de la Mora
Journal:  Med Biol       Date:  1975-06

2.  Facilitation by GABA of the potassium-evoked release of 3-H-noradrenaline from the rat occipital cortex.

Authors:  S Arbilla; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-03       Impact factor: 3.000

3.  The effect of intracerebroventricularly administered GABA on brain monoamine metabolism.

Authors:  B Biswas; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-08       Impact factor: 3.000

4.  Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity.

Authors:  J W Commissiong
Journal:  Biochem Pharmacol       Date:  1985-04-15       Impact factor: 5.858

5.  gamma-Aminobutyric acid reduces the evoked release of [3H]-noradrenaline from sympathetic nerve terminals [proceedings].

Authors:  N G Bowery; A L Hudson
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

6.  gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas.

Authors:  B Scatton; B Zivkovic; J Dedek; K G Lloyd; J Constantinidis; R Tissot; G Bartholini
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

7.  Gamma-guanidinobutyric acid as a convulsive substance.

Authors:  D Jinnai; A Sawai; A Mori
Journal:  Nature       Date:  1966-11-05       Impact factor: 49.962

8.  Delta-guanidinovaleric acid as an endogenous and specific GABA-receptor antagonist: electroencephalographic study.

Authors:  I Yokoi; K Tsuruta; H Shiraga; A Mori; H Shigara
Journal:  Epilepsy Res       Date:  1987-03       Impact factor: 3.045

9.  The biosynthesis of 2-guanidinoethanol in intact mice and isolated perfused rabbit kidneys.

Authors:  Y Watanabe; I Yokoi; A Mori
Journal:  Life Sci       Date:  1987-01-19       Impact factor: 5.037

View more
  1 in total

1.  2-Guanidinoethanol increased dopamine release and 3,4-dihydroxyphenylacetic acid content, but not homovanillic acid content in the rat brain: electroneurochemical and enzymological studies.

Authors:  I Yokoi; H Kabuto; K Hukuyama; Y Nishijima; T Itoh; K Yufu; K Akiyama; A Mori
Journal:  Neurochem Res       Date:  1992-07       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.